Publication

Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step

Otte, A., van de Wiele, C. & Dierckx, R. A., Jan-2009, In : Nuclear Medicine Communications. 30, 1, p. 5-15 11 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Radiolabeled immunotherapy (RIT) is becoming a significant step forward in the treatment management of non-Hodgkin's lymphoma (NHL). In this state-of-the-art review article, general details, practical and health economic aspects, and next steps of RIT in NHL are reviewed from the existing literature and latest abstracts. As Y-90-ibritumomab tiuxetan is the only marketed RIT in NHL in Europe, the special focus of this review is on 90Y-ibritumomab tiuxetan, although the whole spectrum of available RIT concepts is highlighted. There is strong evidence to suggest that RIT is not only a safe and efficacious add-on treatment option in third or second line to chemotherapy, but is also a convincing asset as first-line therapy in various indications of lymphoma. Nucl Med Commun 30:5-15 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Original languageEnglish
Pages (from-to)5-15
Number of pages11
JournalNuclear Medicine Communications
Volume30
Issue number1
Publication statusPublished - Jan-2009

    Keywords

  • chemotherapy, I-131-labeled tositumomab (Bexxar), non-Hodgkin's lymphoma, radiolabeled immunotherapy, Y-90-ibritumomab tiuxetan (Zevalin), IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY, B-CELL LYMPHOMA, ALPHA-EMITTING RADIOIMMUNOCONJUGATE, RADIATION SAFETY CONSIDERATIONS, ANTI-CD22 MONOCLONAL-ANTIBODY, RANDOMIZED CONTROLLED TRIAL, NERVOUS-SYSTEM LYMPHOMA, MALIGNANT-LYMPHOMA, LOW-GRADE, MULTICENTER TRIAL

ID: 4824248